DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff tumour 137.52 malignant 87.3, 87.5, 147.14–15 plaque 35.26, 35.28 clinical features 90.61–3 abscesses 3.38 management 87.5 squamous cell carcinoma secondary complications/co-morbidities 90.63 anal 113.24, 113.25–6 oral lesions 110.10 prevention 142.32 definition 90.59 aseptic abscess syndrome 49.17 paraneoplastic 87.5, 147.15–16, 152.1 subcorneal pustular dermatosis differential diagnosis 90.62–3 breast 116.24 pathophysiology 87.3–4 49.15 disease course 90.63 filler adverse reaction 157.9 predisposing factors 87.4 Vohwinkel syndrome treatment 65.57 epidemiology 90.59–60 glanders 26.53, 26.54 prognosis 87.5 Ackerman tumour see verrucous investigations 90.63 hidradenitis suppurativa 92.4, 92.5 unilateral 87.5 carcinoma management 90.63–4 differential diagnosis 92.7 variants 87.4–5 acne pathophysiology 90.60–1 HIV infection 31.20 vulval 112.21 agminate 90.28 prognosis 90.63 immunodeficiency association 148.15 acanthosis palmaris 147.15–16 antibiotic therapy 19.43 scarring 90.63 intraoral 110.58 Acari 34.35, 34.36, 34.37–9 ocular side effects 109.46 severity 90.63 krokodil abuse 121.3 Acaridae 34.48 arthritis association 154.10 variants 90.62 subungual 95.37–8 accelerated rheumatoid nodulosis 99.15 comedonal 90.1, 90.2–3, 90.21 Propionibacterium acnes 26.43 acantholysis 3.33–4, 66.1, 66.2, 66.4 acetone 95.63 management 90.38, 90.39–40 psychological impact 11.4 pemphigus 50.3 acetyl hexapeptide 3 156.5 mid-facial 90.62 pyogenic sterile arthritis, pyoderma acantholytic dermatoses acetylcholine 2.8, 8.52 treatment algorithm 90.38 gangrenosum and acne Hailey–Hailey disease variants 66.12 atopic eczema 41.15 cosmetica 90.17 syndrome 45.3, 45.8 see also transient acantholytic dermatosis itching in skin disease 83.6 defensin activity 8.14 quality of life measurement 16.6 acantholytic disorders, inherited 66.1–13 acetylcholine receptor antibodies 50.3 detergent 90.17 surgery 20.47 see also Darier disease; Hailey–Hailey Achenbach syndrome 101.6, 123.13 ectopic 92.1 acne aestivalis 93.6 disease achondroplasia, osteogenesis imperfecta endocrine disorder skin signs 149.10 acne conglobata 90.50–1, 90.54–6, 92.2, acantholytic dyskeratosis 71.24 differential diagnosis 72.10 environmental, differential 154.10 focal 110.19 aciclovir 19.44 diagnosis 90.57 acne fulminans differential acanthoma fissuratum 123.13–14 erythema multiforme 47.6 environmental pollution 90.56–7 diagnosis 90.52, 90.56 acanthosis 3.34 herpes simplex virus excoriée 90.23 assessment 90.56 Bowen disease 142.17 inCOPYRIGHTED HIV 31.23 MATERIALgranulomatous 90.24 associated diseases 90.54 peristomal papules 114.111 neonatal 116.22 hidradenitis suppurativa 92.2 clinical features 90.55–6 acanthosis nigricans 64.3, 87.2–5, 147.14–15 post-herpetic neuralgia 84.4–5 hirsutism association 89.65 complications 90.56 acquired generalized resistance 31.23 hyperandrogenism 145.18 definition 90.54 lipodystrophy 100.3 topical 18.13 infantile 90.59, 90.61–2, 90.63, 117.5 differential diagnosis 90.55 acral 87.4–5 varicella-zoster virus 25.30, 31.23 differential diagnosis 90.62 dissecting cellulitis of scalp associated disorders 87.3 acid glycosaminoglycans 59.1 inversa 92.1 association 107.8 benign 147.14 acid lipase 65.10 isotretinoin treatment 11.4 epidemiology 90.54 clinical features 87.4–5 acid orcein–Giemsa stain 3.8, 3.9 joint symptom association 154.10 genetics 90.54 confluent and reticulated papillomatosis acid phosphatase 2.43, 8.41 keloid-like 96.46, 96.47 hidradenitis suppurativa differential differential diagnosis 87.7 lysosomal 8.44 mechanical 90.24 diagnosis 113.21 congenital generalized lipodystrophies acids, chemical burns 129.12 mid-childhood 90.59, 90.60, 90.62 infants 90.62 74.1 Acinetobacter 26.50 differential diagnosis 90.63 management 90.56, 90.57 Darier disease differential Acinetobacter baumannii 34.18 necrotica 90.32 pathophysiology 90.54 diagnosis 66.4 acitretin 19.37, 31.16 neonatal 90.59, 90.61, 90.63 acné excoriée 86.15–16, 90.23 Rook’s Textbook of Dermatology, Ninth Edition. Edited by Christopher Griffiths, Jonathan Barker, Tanya Bleiker, Robert Chalmers and Daniel Creamer. © 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd. Companion website: www.rooksdermatology.com bindex.indd 1 27 March 2017 8:04 PM 2 Index acne fulminans 90.50–3, 154.10 systemic therapy 90.41–4 acral peeling skin syndrome (APSS) 65.27, actin 3.21 acne conglobata differential topical therapy 90.40–1 71.6, 71.7 actinic cheilitis 110.78–9 diagnosis 90.52, 90.56 papulopustular rosacea differential keratolysis exfoliativa differential carbon dioxide laser ablation 23.18 assessment 90.52–3 diagnosis 91.10 diagnosis 87.24 photodynamic therapy 22.5 associated disorders 90.50–1 pathophysiology 90.18–20 acral persistent papular mucinosis 59.6, actinic comedonal plaque 96.3 clinical features 90.51–2 periorificial dermatitis differential 59.7 actinic dermatitis see chronic actinic complications 90.53 diagnosis 91.18 acral self-healing collodion baby 116.19 dermatitis definition 90.50 photoaggravated, actinic folliculitis acroangiodermatitis 101.5 actinic elastosis see solar elastosis differential diagnosis 90.52 differential diagnosis 93.6 Kaposi sarcoma, differential actinic folliculitis 93.6 disease course 90.53 predisposing factors 90.12–13, 90.14–16, diagnosis 139.4 actinic granuloma 96.25–7 epidemiology 90.50–1 90.16–18 acrocyanosis 81.10, 125.5–6 solar elastosis association 96.3 genetics 90.51 pregnancy 90.17, 115.8–9 neonates 116.3 actinic keratoses 142.1–7, 142.8, 142.9–11 infections 90.51 prognosis 90.36 proximal nail fold capillaroscopy 95.52 basal cell carcinoma association 125.13, investigations 90.52–3 Pseudomonas aeruginosa infection 26.52 Raynaud phenomenon differential 141.2 isotretinoin-induced flare 90.51 psychological problem association 90.23 diagnosis 125.9 benign lichenoid keratosis differential management 90.53 psychosocial effects 90.34–5 Sneddon syndrome 101.21 diagnosis 133.7 pathophysiology 90.51 pyogenic granuloma 90.36 acrodermatitis chronica atrophicans 96.13– Bowen disease differential prognosis 90.53 quality of life impact 90.33, 90.34, 90.34 14, 96.19 diagnosis 142.19 variants 90.52 rosacea conglobata differential Lyme disease 140.38 bowenoid 142.3 acne inversa see hidradenitis suppurativa diagnosis 91.16 sclerosing panniculitis differential causative organisms 142.3 acne keloidalis scarring 90.22, 90.23, 90.24, 90.35 diagnosis 99.29 chondrodermatitis nodularis differential nuchae 93.3–4, 123.16 mimics 90.32 acrodermatitis chronica migrans 26.70 diagnosis 108.9 scarring 90.32 seborrhoea 90.36 acrodermatitis continua of clinical features 142.3–6 acne mechanica 123.15, 123.16 severe Hallopeau 35.40–2 immunocompromised acne of chemical origin treatment 90.44–8 clinical features 35.41–2 patients 146.10–11 clinical features 130.11–12 treatment algorithm 90.39 definition 35.40 complications/co-morbidity 142.6 differential diagnosis 130.11 severity rating 90.32–3, 90.36, 90.37 differential diagnosis 35.42 cutaneous horn differential hidradenitis suppurativa differential sinus tracts 90.22, 90.23 epidemiology 35.41 diagnosis 142.12 diagnosis 113.21 sleep deprivation 90.16–17 investigations 35.42 definition 142.1 management 130.12 smoking 90.16 management 35.42 differential diagnosis 142.4–5 occupational disorders 130.10–12 stress factors 90.16–17 pathophysiology 35.41 disease course 142.6 Acne Quality of Life Scale (AQOL) 16.6 suicide risk 90.34–5 psoriasis 95.41 disseminated superficial actinic Acne Symptom and Impact Scale tuberous sclerosis complex differential radiotherapy 24.6 porokeratosis differential (ASIS) 16.6 diagnosis 80.12 acrodermatitis dysmetabolica 63.26, 71.24 diagnosis 142.16 acne vulgaris 90.1–3, 90.3–4, 90.5–6, 90.7, UV radiation 90.17 acrodermatitis enteropathica 63.26, epidemiology 142.2 90.8–13, 90.14–16, 90.16–50 variants 90.22–4 81.17–18 eyelid 109.46 acneform drug eruption differential acneform eruptions 120.3 breastfed infants 63.25–6 Flegel disease differential diagnosis 118.17 chemical
Recommended publications
  • PRIMARY HYPERHIDROSIS Prevalence and Impacts for the Individual

    PRIMARY HYPERHIDROSIS Prevalence and Impacts for the Individual

    PRIMARY HYPERHIDROSIS Prevalence and impacts for the individual Alexander Shayesteh Afshar Department of Public Health and Clinical Medicine Dermatology and Venereology Umeå 2018 Copyright © Alexander Shayesteh Afshar 2018 This work is protected by the Swedish Copyright Legislation (Act 1960:729) Dissertation for PhD ISBN: 978-91-7601-822-4 ISSN: 0346-6612 New Series No 1940 Cover art: “Drop Beads” by Grant Ware and Alexander Shayesteh Afshar Electronic version available at: http://umu.diva-portal.org/ Printed by: Umu Print Service Umeå, Sweden 2018 To Ladan, Gabriel and Isabell In medicine we ought to know the causes of sickness and health. And because health and sickness and their causes are sometimes manifest, and sometimes hidden and not to be comprehended except by the study of symptoms, we must also study the symptoms of health and disease. Avicenna 973-1037 CE Table of contents Abstract ............................................................................................ iii Abbreviations .................................................................................... v Sammanfattning på svenska ............................................................ vi List of papers .................................................................................. vii Introduction ....................................................................................... 1 Sweat ................................................................................................................................. 1 Sweat glands ....................................................................................................................
  • Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    BMB Rep. 2015; 48(12): 647-654 BMB www.bmbreports.org Reports Invited Mini Review Primary cilia in energy balance signaling and metabolic disorder Hankyu Lee, Jieun Song, Joo Hyun Jung & Hyuk Wan Ko* College of Pharmacy, Dongguk University, Goyang 10326, Korea Energy homeostasis in our body system is maintained by bal- complex, due to many confounding genetics and environ- ancing the intake and expenditure of energy. Excessive accu- mental factors equivocally affecting the progress of the disease. mulation of fat by disrupting the balance system causes over- Moreover, metabolic disorders are interrelated diseases exem- weight and obesity, which are increasingly becoming global plified by the association of obesity with insulin resistance, health concerns. Understanding the pathogenesis of obesity fo- leading to development of type II diabetes (2). Genetic factors cused on studying the genes related to familial types of for obesity are poorly understood, and recent progress by ge- obesity. Recently, a rare human genetic disorder, ciliopathy, nome-wide association studies support the notion of polygenic links the role for genes regulating structure and function of a features of obesity which suggests that multiple genes, tissues cellular organelle, the primary cilium, to metabolic disorder, and pathways contribute to the disease (3, 4). Intriguing subset obesity and type II diabetes. Primary cilia are microtubule of genes associated with obesity cause a dysfunction of pri- based hair-like membranous structures, lacking motility and mary cilia, which results in a rare pleiotropic human disorder functions such as sensing the environmental cues, and trans- called ciliopathy (5, 6). Primary cilia are microtubule based ducing extracellular signals within the cells.
  • Research Article

    Research Article

    z Available online at http://www.journalcra.com INTERNATIONAL JOURNAL OF CURRENT RESEARCH International Journal of Current Research Vol. 11, Issue, 12, pp.8946-8949, December, 2019 DOI: https://doi.org/10.24941/ijcr.37495.12.2019 ISSN: 0975-833X RESEARCH ARTICLE SKIN: A WINDOW FOR THYROID DISEASE 1Neethu Mary George, 2,*Amruthavalli Potlapati and 3Narendra Gangaiah 1 Resident, Department of Dermatology, Sri Siddhartha Medical College, Karnataka 2Assistant Professor, Department of Dermatology, Sri Siddhartha Medical College, Karnataka 3Professor and HOD, Department of Dermatology, Sri Siddhartha Medical College, Karnataka ARTICLE INFO ABSTRACT Article History: Introduction: Endocrine conditions form a major bulk of those visiting physicians and most of the Received 24th September, 2019 conditions warrant immediate and long term treatment which otherwise can indirectly affect all the Received in revised form organ systems and adversely affect the ‘health’ of a person. Thyroid diseases are one of the most 28th October, 2019 common endocrinological conditions with varying skin and appandageal manifestations. Skin is an Accepted 15th November, 2019 organ that is visible to naked eyes and can at times show certain manifestations which point to an Published online 31st December, 2019 underlying disease. Unless the clinician has high index of suspicion, such conditions can go undetected. Hence it becomes imperative for clinicians and Dermatologists to have an idea about the Key Words: cutaneous manifestations of endocrinological conditions and hence the study assess the skin Hyperthyroid, Hypothyroid, Cutaneous manifestations in recently detected hyper and hypothyroid patients. Objectives: To evaluate the cutaneous, hair and nail findings and associated conditions in acquired thyroid disorders. Manifestations, Pincer Nail.
  • Compensation for Occupational Skin Diseases

    Compensation for Occupational Skin Diseases

    ORIGINAL ARTICLE http://dx.doi.org/10.3346/jkms.2014.29.S.S52 • J Korean Med Sci 2014; 29: S52-58 Compensation for Occupational Skin Diseases Han-Soo Song1 and Hyun-chul Ryou2 The Korean list of occupational skin diseases was amended in July 2013. The past list was constructed according to the causative agent and the target organ, and the items of that 1 Department of Occupational and Environmental list had not been reviewed for a long period. The revised list was reconstructed to include Medicine, College of Medicine, Chosun University, Gwangju; 2Teo Center of Occupational and diseases classified by the International Classification of Diseases (10th version). Therefore, Environmental Medicine, Changwon, Korea the items of compensable occupational skin diseases in the amended list in Korea comprise contact dermatitis; chemical burns; Stevens-Johnson syndrome; tar-related skin diseases; Received: 19 December 2013 infectious skin diseases; skin injury-induced cellulitis; and skin conditions resulting from Accepted: 2 May 2014 physical factors such as heat, cold, sun exposure, and ionized radiation. This list will be Address for Correspondence: more practical and convenient for physicians and workers because it follows a disease- Han-Soo Song, MD based approach. The revised list is in accordance with the International Labor Organization Department of Occupational and Environmental Medicine, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, list and is refined according to Korean worker’s compensation and the actual occurrence of Gwangju 501-717, Korea occupational skin diseases. However, this revised list does not perfectly reflect the actual Tel: +82.62-220-3689, Fax: +82.62-443-5035 E-mail: [email protected] status of skin diseases because of the few cases of occupational skin diseases, incomplete statistics of skin diseases, and insufficient scientific evidence.
  • General Dermatology an Atlas of Diagnosis and Management 2007

    General Dermatology an Atlas of Diagnosis and Management 2007

    An Atlas of Diagnosis and Management GENERAL DERMATOLOGY John SC English, FRCP Department of Dermatology Queen's Medical Centre Nottingham University Hospitals NHS Trust Nottingham, UK CLINICAL PUBLISHING OXFORD Clinical Publishing An imprint of Atlas Medical Publishing Ltd Oxford Centre for Innovation Mill Street, Oxford OX2 0JX, UK tel: +44 1865 811116 fax: +44 1865 251550 email: [email protected] web: www.clinicalpublishing.co.uk Distributed in USA and Canada by: Clinical Publishing 30 Amberwood Parkway Ashland OH 44805 USA tel: 800-247-6553 (toll free within US and Canada) fax: 419-281-6883 email: [email protected] Distributed in UK and Rest of World by: Marston Book Services Ltd PO Box 269 Abingdon Oxon OX14 4YN UK tel: +44 1235 465500 fax: +44 1235 465555 email: [email protected] © Atlas Medical Publishing Ltd 2007 First published 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. A catalogue record of this book is available from the British Library ISBN-13 978 1 904392 76 7 Electronic ISBN 978 1 84692 568 9 The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations.
  • European Guideline Chronic Pruritus Final Version

    European Guideline Chronic Pruritus Final Version

    EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar
  • Regulatory News

    Regulatory News

    WHO Drug Information Vol. 28, No. 4, 2014 Regulatory news Ebola curative – transfusions of whole blood or blood plasma from recovered patients Update on treatments and vaccines have been scheduled to be conducted in Liberia, in line with WHO technical The Ebola crisis has prompted an guidelines (4). unprecedented cooperation between regulators In September the European Medicines to support WHO and to advise on possible Agency (EMA) established an expert pathways for the development, evaluation and group to review available information approval of medicines to fight Ebola. Progress on Ebola experimental treatments – towards provision of treatments and vaccines is excluding convalescent therapies – and summarized below. invited developers to submit their data (5). In August 2014, a WHO-convened panel Vaccines had agreed unanimously that is ethically On 29–30 September, 70 experts acceptable to use of experimental attended a WHO-convened consultation medicines and vaccines under the on Ebola vaccines. They took stock of the exceptional circumstances of the Ebola many ongoing efforts to rapidly evaluate epidemic (1). In early September, WHO the safety and efficacy of Ebola vaccines convened a consultation on potential for deployment as soon as possible to Ebola therapies and vaccines (2). The critical frontline workers and ultimately to importance of supportive care and populations at risk in mass vaccination community response was stressed in this campaigns. Two candidate vaccines have and subsequent discussions. clinical-grade vials available for safety trials. (6) Treatments In October, WHO convened industry In September, more than 200 experts leaders and key partners to discuss trials from around the world met at WHO and production of Ebola vaccine (7).
  • Dyskeratosis Congenita Precision Panel Overview Indications Clinical

    Dyskeratosis Congenita Precision Panel Overview Indications Clinical

    Dyskeratosis Congenita Precision Panel Overview Dyskeratosis Congenita (DKC) is a rare, progressive bone marrow failure syndrome characterized by reticulated skin hyperpigmentation, nail dystrophy and oral leukoplakia. Patients usually present with symptoms of skin hyperpigmentation and nail changes during the first decade of life. It is caused by germline mutations in genes regulating telomere maintenance, resulting in very short telomeres. DKC is a genetically heterogeneous with X-linked recessive form being the most common, autosomal dominant and autosomal recessive subtypes based on different patters of inheritance. Early mortality is associated with bone marrow failure, infections, lung and pulmonary complications as well as malignancy. The Igenomix Dyskeratosis Congenita Precision Panel can be used for an accurate and directed diagnosis as well as differential diagnosis of reticulate pigmentary disorders ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Dyskeratosis Congenita Precision Panel is used for patients with a clinical diagnosis or suspicion with or without the following symptoms: ‐ Abnormal skin pigmentation (tan-to-gray hyperpigmented or hypopigmented macules and patches) ‐ Nail dystrophy ‐ Skin atrophy and telangiectasia ‐ Alopecia of the skin, eyebrows and eyelashes ‐ Mucosal leukoplakia ‐ Bone marrow failure ‐ Dental manifestations Clinical Utility The clinical utility of this panel is: ‐ The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. 1 ‐ Early initiation of treatment involving a multidisciplinary team in the form of hematopoietic stem cell transplantation as well as medical care to prevent complications and early surveillance of malignancy.
  • Pruritus: Scratching the Surface

    Pruritus: Scratching the Surface

    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
  • The Genetics and Clinical Manifestations of Telomere Biology Disorders Sharon A

    The Genetics and Clinical Manifestations of Telomere Biology Disorders Sharon A

    REVIEW The genetics and clinical manifestations of telomere biology disorders Sharon A. Savage, MD1, and Alison A. Bertuch, MD, PhD2 3 Abstract: Telomere biology disorders are a complex set of illnesses meric sequence is lost with each round of DNA replication. defined by the presence of very short telomeres. Individuals with classic Consequently, telomeres shorten with aging. In peripheral dyskeratosis congenita have the most severe phenotype, characterized blood leukocytes, the cells most extensively studied, the rate 4 by the triad of nail dystrophy, abnormal skin pigmentation, and oral of attrition is greatest during the first year of life. Thereafter, leukoplakia. More significantly, these individuals are at very high risk telomeres shorten more gradually. When the extent of telo- of bone marrow failure, cancer, and pulmonary fibrosis. A mutation in meric DNA loss exceeds a critical threshold, a robust anti- one of six different telomere biology genes can be identified in 50–60% proliferative signal is triggered, leading to cellular senes- of these individuals. DKC1, TERC, TERT, NOP10, and NHP2 encode cence or apoptosis. Thus, telomere attrition is thought to 1 components of telomerase or a telomerase-associated factor and TINF2, contribute to aging phenotypes. 5 a telomeric protein. Progressively shorter telomeres are inherited from With the 1985 discovery of telomerase, the enzyme that ex- generation to generation in autosomal dominant dyskeratosis congenita, tends telomeric nucleotide repeats, there has been rapid progress resulting in disease anticipation. Up to 10% of individuals with apparently both in our understanding of basic telomere biology and the con- acquired aplastic anemia or idiopathic pulmonary fibrosis also have short nection of telomere biology to human disease.
  • Copyrighted Material

    Copyrighted Material

    Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01